{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T08:42:43Z","timestamp":1792572163836,"version":"4.5.0"},"reference-count":43,"publisher":"American Chemical Society (ACS)","issue":"10","license":[{"start":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T00:00:00Z","timestamp":1790121600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T00:00:00Z","timestamp":1790121600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T00:00:00Z","timestamp":1790121600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-045"}],"funder":[{"DOI":"10.13039\/501100006769","name":"Russian Science Foundation","doi-asserted-by":"publisher","award":["25-13-20064"],"award-info":[{"award-number":["25-13-20064"]}],"id":[{"id":"10.13039\/501100006769","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,10,21]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Herein, we report the synthesis and biological evaluation of the first phospholipid prodrug of gedatolisib, a dual PI3K\/mTOR inhibitor, and liposomal nanoparticles based on this conjugate. The liposomes were designed for selective cleavage by phospholipase A2, enabling the release of the active drug from the gedatolisib\u2212phospholipid conjugate. Compared with free gedatolisib, the liposomal formulation demonstrated cytotoxicity that was 2\u22123 orders of magnitude lower across several cancer cell lines. In vivo studies using the EMT6 breast cancer model showed that the liposomal prodrug exhibited superior antitumor efficacy while being substantially less hepatotoxic than free gedatolisib, which displayed negligible antitumor activity. This phospholipid conjugation strategy represents a promising approach for potentially improving the therapeutic index of gedatolisib.<\/jats:p>","DOI":"10.1021\/acs.bioconjchem.6c00278","type":"journal-article","created":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T05:29:02Z","timestamp":1790314142000},"page":"1999-2010","source":"Crossref","is-referenced-by-count":0,"title":["Design, Synthesis, and Biological Evaluation of a Novel Gedatolisib\u2212Phospholipid Conjugate and Liposomal Formulations Based Thereon"],"prefix":"10.1021","volume":"37","author":[{"given":"Irina P.","family":"Fonareva","sequence":"first","affiliation":[{"name":"Lobachevsky State University of Niznhy Novgorod , 23 Gagarin Prosp . , ,","place":["Nizhny Novgorod, Russian Federation, 603022"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna S.","family":"Alekseeva","sequence":"additional","affiliation":[{"name":"Russian Academy of Sciences , , ul. Miklukho-Maklaya 16\/10 , ,","place":["Moscow, Russian Federation, 117997"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elena V.","family":"Svirshchevskaya","sequence":"additional","affiliation":[{"name":"Russian Academy of Sciences , , ul. Miklukho-Maklaya 16\/10 , ,","place":["Moscow, Russian Federation, 117997"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elena L.","family":"Vodovozova","sequence":"additional","affiliation":[{"name":"Russian Academy of Sciences , , ul. Miklukho-Maklaya 16\/10 , ,","place":["Moscow, Russian Federation, 117997"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vyacheslav E.","family":"Safonov","sequence":"additional","affiliation":[{"name":"Lobachevsky State University of Niznhy Novgorod , 23 Gagarin Prosp . , ,","place":["Nizhny Novgorod, Russian Federation, 603022"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4889-8617","authenticated-orcid":true,"given":"Alexey Yu.","family":"Fedorov","sequence":"additional","affiliation":[{"name":"Lobachevsky State University of Niznhy Novgorod , 23 Gagarin Prosp . , ,","place":["Nizhny Novgorod, Russian Federation, 603022"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2194-1814","authenticated-orcid":true,"given":"Ekaterina S.","family":"Shchegravina","sequence":"additional","affiliation":[{"name":"Lobachevsky State University of Niznhy Novgorod , 23 Gagarin Prosp . , ,","place":["Nizhny Novgorod, Russian Federation, 603022"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"316","published-online":{"date-parts":[[2026,9,23]]},"reference":[{"issue":"1","key":"2026102103084188400_cit1","doi-asserted-by":"publisher","first-page":"138","DOI":"10.1186\/s12943-023-01827-6","article-title":"PI3K\/AKT\/MTOR Signaling Transduction Pathway and Targeted Therapies in Cancer","volume":"22","author":"Glaviano","year":"2023","journal-title":"Mol. Cancer"},{"key":"2026102103084188400_cit2","doi-asserted-by":"publisher","first-page":"116850","DOI":"10.1016\/j.bcp.2025.116850","article-title":"Strategic Advancements in Targeting the PI3K\/AKT\/MTOR Pathway for Breast Cancer Therapy","volume":"236","author":"Garg","year":"2025","journal-title":"Biochem. Pharmacol."},{"issue":"6","key":"2026102103084188400_cit3","doi-asserted-by":"publisher","first-page":"4587","DOI":"10.1007\/s11033-020-05435-1","article-title":"Role of PI3K\/AKT Pathway in Cancer: The Framework of Malignant Behavior","volume":"47","author":"Jiang","year":"2020","journal-title":"Mol. Biol. Rep."},{"issue":"24","key":"2026102103084188400_cit4","doi-asserted-by":"publisher","first-page":"16033","DOI":"10.1021\/acs.jmedchem.2c01070","article-title":"Targeting the PI3K\/AKT\/MTOR Signaling Pathway in the Treatment of Human Diseases: Current Status, Trends, and Solutions","volume":"65","author":"Huang","year":"2022","journal-title":"J. Med. Chem."},{"key":"2026102103084188400_cit5","doi-asserted-by":"publisher","first-page":"648636","DOI":"10.3389\/fphar.2021.648636","article-title":"PI3K\/AKT Signal Pathway: A Target of Natural Products in the Prevention and Treatment of Alzheimer\u2019s Disease and Parkinson\u2019s Disease","volume":"12","author":"Long","year":"2021","journal-title":"Front. Pharmacol."},{"issue":"12","key":"2026102103084188400_cit6","doi-asserted-by":"publisher","first-page":"4098","DOI":"10.3390\/ijms19124098","article-title":"PI3Kinases in Diabetes Mellitus and Its Related Complications","volume":"19","author":"Maffei","year":"2018","journal-title":"Int. J. Mol. Sci."},{"issue":"4","key":"2026102103084188400_cit7","doi-asserted-by":"publisher","first-page":"876","DOI":"10.1007\/s43440-023-00504-1","article-title":"The Warburg Effect: A Score for Many Instruments in the Concert of Cancer and Cancer Niche Cells","volume":"75","author":"Jaworska","year":"2023","journal-title":"Pharmacol. Reports"},{"key":"2026102103084188400_cit8","doi-asserted-by":"publisher","first-page":"662232","DOI":"10.3389\/fphar.2021.662232","article-title":"AKT Inhibitors: New Weapons in the Fight Against Breast Cancer?","volume":"12","author":"Martorana","year":"2021","journal-title":"Front. Pharmacol."},{"issue":"7448","key":"2026102103084188400_cit9","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1038\/nature12122","article-title":"MTOR Kinase Structure, Mechanism and Regulation","volume":"497","author":"Yang","year":"2013","journal-title":"Nature"},{"issue":"1","key":"2026102103084188400_cit10","doi-asserted-by":"publisher","first-page":"375","DOI":"10.1038\/s41392-023-01608-z","article-title":"Multifaceted Role of MTOR (Mammalian Target of Rapamycin) Signaling Pathway in Human Health and Disease","volume":"8","author":"Panwar","year":"2023","journal-title":"Signal Transduct. Target. Ther."},{"issue":"41","key":"2026102103084188400_cit11","doi-asserted-by":"publisher","first-page":"5486","DOI":"10.1038\/onc.2008.244","article-title":"Class I PI3K in Oncogenic Cellular Transformation","volume":"27","author":"Zhao","year":"2008","journal-title":"Oncogene"},{"issue":"3","key":"2026102103084188400_cit12","doi-asserted-by":"publisher","first-page":"635","DOI":"10.1007\/s00204-023-03440-4","article-title":"Development and Safety of PI3K Inhibitors in Cancer","volume":"97","author":"Yu","year":"2023","journal-title":"Arch. Toxicol."},{"key":"2026102103084188400_cit13","doi-asserted-by":"publisher","first-page":"1070660","DOI":"10.3389\/fimmu.2022.1070660","article-title":"Safety and Efficacy of Dual PI3K-\u03b4, \u03b3 Inhibitor, Duvelisib in Patients with Relapsed or Refractory Lymphoid Neoplasms: A Systematic Review and Meta-Analysis of Prospective Clinical Trials","volume":"13","author":"Wang","year":"2023","journal-title":"Front. Immunol."},{"issue":"1","key":"2026102103084188400_cit14","doi-asserted-by":"publisher","first-page":"346","DOI":"10.1182\/hematology.2020000119","article-title":"Managing Toxicities of Phosphatidylinositol-3-Kinase (PI3K) Inhibitors","volume":"2020","author":"Hanlon","year":"2020","journal-title":"Hematology"},{"issue":"1","key":"2026102103084188400_cit15","doi-asserted-by":"publisher","first-page":"313","DOI":"10.1186\/s13046-024-03207-4","article-title":"AKT Kinases as Therapeutic Targets","volume":"43","author":"Hassan","year":"2024","journal-title":"J. Exp. Clin. Cancer Res."},{"issue":"8","key":"2026102103084188400_cit16","doi-asserted-by":"publisher","first-page":"6052","DOI":"10.1021\/acs.jmedchem.4c00075","article-title":"Akt Inhibitor Advancements: From Capivasertib Approval to Covalent-Allosteric Promises","volume":"67","author":"Pervanidis","year":"2024","journal-title":"J. Med. Chem."},{"issue":"1","key":"2026102103084188400_cit17","doi-asserted-by":"publisher","first-page":"1726078","DOI":"10.1155\/2017\/1726078","article-title":"Resistance to MTORC1 Inhibitors in Cancer Therapy: From Kinase Mutations to Intratumoral Heterogeneity of Kinase Activity","volume":"2017","author":"Faes","year":"2017","journal-title":"Oxid. Med. Cell. Longev."},{"issue":"2","key":"2026102103084188400_cit18","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1016\/j.ccr.2011.12.024","article-title":"Inhibition of PI3K\/MTOR Leads to Adaptive Resistance in Matrix-Attached Cancer Cells","volume":"21","author":"Muranen","year":"2012","journal-title":"Cancer Cell"},{"issue":"8","key":"2026102103084188400_cit19","doi-asserted-by":"publisher","first-page":"550","DOI":"10.1038\/nrc2664","article-title":"Targeting PI3K Signalling in Cancer: Opportunities, Challenges and Limitations","volume":"9","author":"Engelman","year":"2009","journal-title":"Nat. Rev. Cancer"},{"issue":"2","key":"2026102103084188400_cit20","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1007\/s11912-010-0091-6","article-title":"Development of Phosphoinositide-3 Kinase Pathway Inhibitors for Advanced Cancer","volume":"12","author":"Cleary","year":"2010","journal-title":"Curr. Oncol. Rep."},{"key":"2026102103084188400_cit21","doi-asserted-by":"publisher","first-page":"875372","DOI":"10.3389\/fphar.2022.875372","article-title":"Recent Advances in Dual PI3K\/MTOR Inhibitors for Tumour Treatment","volume":"13","author":"Wu","year":"2022","journal-title":"Front. Pharmacol."},{"issue":"6","key":"2026102103084188400_cit22","doi-asserted-by":"publisher","first-page":"2636","DOI":"10.1021\/jm901830p","article-title":"Bis(Morpholino-1,3,5-Triazine) Derivatives: Potent Adenosine 5\u2032-Triphosphate Competitive Phosphatidylinositol-3-Kinase\/Mammalian Target of Rapamycin Inhibitors: Discovery of Compound 26 (PKI-587), a Highly Efficacious Dual Inhibitor","volume":"53","author":"Venkatesan","year":"2010","journal-title":"J. Med. Chem."},{"issue":"10","key":"2026102103084188400_cit23","doi-asserted-by":"publisher","first-page":"3193","DOI":"10.1158\/1078-0432.CCR-10-1694","article-title":"Antitumor Efficacy of PKI-587, a Highly Potent Dual PI3K\/MTOR Kinase Inhibitor","volume":"17","author":"Mallon","year":"2011","journal-title":"Clin. Cancer Res."},{"issue":"1","key":"2026102103084188400_cit24","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1038\/s41523-024-00648-0","article-title":"Gedatolisib Shows Superior Potency and Efficacy versus Single-Node PI3K\/AKT\/MTOR Inhibitors in Breast Cancer Models","volume":"10","author":"Rossetti","year":"2024","journal-title":"npj Breast Cancer"},{"issue":"18","key":"2026102103084188400_cit25","doi-asserted-by":"publisher","first-page":"8038","DOI":"10.1021\/jm300881a","article-title":"Synthesis and Characterization of a Novel Prostate Cancer-Targeted Phosphatidylinositol-3-Kinase Inhibitor Prodrug","volume":"55","author":"Baiz","year":"2012","journal-title":"J. Med. Chem."},{"issue":"18","key":"2026102103084188400_cit26","doi-asserted-by":"publisher","first-page":"3319","DOI":"10.1016\/j.ejca.2012.06.027","article-title":"Phase I Pharmacokinetic and Pharmacodynamic Study of the Pan-PI3K\/MTORC Vascular Targeted pro-Drug SF1126 in Patients with Advanced Solid Tumours and B-Cell Malignancies","volume":"48","author":"Mahadevan","year":"2012","journal-title":"Eur. J. Cancer"},{"key":"2026102103084188400_cit27","doi-asserted-by":"publisher","first-page":"160","DOI":"10.1016\/j.jconrel.2015.10.037","article-title":"Cytotoxicity of PEGylated Liposomes Co-Loaded with Novel pro-Apoptotic Drug NCL-240 and the MEK Inhibitor Cobimetinib against Colon Carcinoma in Vitro","volume":"220","author":"Sriraman","year":"2015","journal-title":"J. Control. Release"},{"issue":"6","key":"2026102103084188400_cit28","doi-asserted-by":"publisher","first-page":"1472","DOI":"10.3390\/cells10061472","article-title":"Phospholipase A2 Drives Tumorigenesis and Cancer Aggressiveness through Its Interaction with Annexin A1","volume":"10","author":"Vecchi","year":"2021","journal-title":"Cells"},{"issue":"2","key":"2026102103084188400_cit29","doi-asserted-by":"publisher","first-page":"1353","DOI":"10.3390\/ijms24021353","article-title":"The Phospholipase A2 Superfamily: Structure, Isozymes, Catalysis, Physiologic and Pathologic Roles","volume":"24","author":"Khan","year":"2023","journal-title":"Int. J. Mol. Sci."},{"issue":"7","key":"2026102103084188400_cit30","doi-asserted-by":"publisher","first-page":"2895","DOI":"10.1021\/jm501371s","article-title":"Organic Carbamates in Drug Design and Medicinal Chemistry","volume":"58","author":"Ghosh","year":"2015","journal-title":"J. Med. Chem."},{"issue":"5","key":"2026102103084188400_cit31","doi-asserted-by":"publisher","first-page":"699","DOI":"10.1016\/j.apsb.2018.05.005","article-title":"Human Carboxylesterases: A Comprehensive Review","volume":"8","author":"Wang","year":"2018","journal-title":"Acta Pharm. Sin. B"},{"issue":"2","key":"2026102103084188400_cit32","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1016\/j.jconrel.2012.03.020","article-title":"Doxil(R)--the First FDA-Approved Nano-Drug: Lessons Learned","volume":"160","author":"Barenholz","year":"2012","journal-title":"J. Control. Release"},{"key":"2026102103084188400_cit33","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1016\/j.addr.2018.07.007","article-title":"Tumor Targeting via EPR: Strategies to Enhance Patient Responses","volume":"130","author":"Golombek","year":"2018","journal-title":"Adv. Drug Deliv. Rev."},{"issue":"1","key":"2026102103084188400_cit34","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1021\/acs.oprd.7b00298","article-title":"New and Practical Synthesis of Gedatolisib","volume":"22","author":"Liu","year":"2018","journal-title":"Org. Process Res. Dev."},{"key":"2026102103084188400_cit35","doi-asserted-by":"publisher","first-page":"114614","DOI":"10.1016\/j.addr.2022.114614","article-title":"The Tumor EPR Effect for Cancer Drug Delivery: Current Status, Limitations, and Alternatives","volume":"191","author":"Sun","year":"2022","journal-title":"Adv. Drug Deliv. Rev."},{"issue":"7","key":"2026102103084188400_cit36","doi-asserted-by":"publisher","first-page":"2451","DOI":"10.1529\/biophysj.106.096362","article-title":"Solution PH Alters Mechanical and Electrical Properties of Phosphatidylcholine Membranes: Relation between Interfacial Electrostatics, Intramembrane Potential, and Bending Elasticity","volume":"92","author":"Zhou","year":"2007","journal-title":"Biophys. J."},{"issue":"11","key":"2026102103084188400_cit37","doi-asserted-by":"publisher","first-page":"7492","DOI":"10.1074\/jbc.275.11.7492","article-title":"Novel Human Secreted Phospholipase A2 with Homology to the Group III Bee Venom Enzyme","volume":"275","author":"Valentin","year":"2000","journal-title":"J. Biol. Chem."},{"issue":"18","key":"2026102103084188400_cit38","doi-asserted-by":"publisher","first-page":"6945","DOI":"10.1128\/MCB.20.18.6945-6957.2000","article-title":"Deficiency of PTEN in Jurkat T Cells Causes Constitutive Localization of Itk to the Plasma Membrane and Hyperresponsiveness to CD3 Stimulation","volume":"20","author":"Shan","year":"2000","journal-title":"Mol. Cell. Biol."},{"issue":"16","key":"2026102103084188400_cit39","doi-asserted-by":"publisher","first-page":"22128","DOI":"10.18632\/oncotarget.8031","article-title":"Identification of Differential PI3K Pathway Target Dependencies in T-Cell Acute Lymphoblastic Leukemia through a Large Cancer Cell Panel Screen","volume":"7","author":"Lynch","year":"2016","journal-title":"Oncotarget"},{"issue":"10","key":"2026102103084188400_cit40","doi-asserted-by":"publisher","first-page":"921","DOI":"10.1097\/00001813-199911000-00008","article-title":"In Vitro Cellular Accumulation and Cytotoxicity of Liposomal and Conventional Formulations of Daunorubicin and Doxorubicin in Resistant K562 Cells","volume":"10","author":"Wang","year":"1999","journal-title":"Anticancer. Drugs"},{"key":"2026102103084188400_cit41","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1016\/j.imlet.2017.01.010","article-title":"CD19, from Bench to Bedside","volume":"183","author":"Li","year":"2017","journal-title":"Immunol. Lett."},{"issue":"1","key":"2026102103084188400_cit42","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1016\/S0021-9673(00)85249-8","article-title":"A Universal Reagent for Phospholipid Analysis","volume":"114","author":"Vaskovsky","year":"1975","journal-title":"J. Chromatogr."},{"issue":"4","key":"2026102103084188400_cit43","doi-asserted-by":"publisher","first-page":"1098","DOI":"10.1021\/acs.bioconjchem.9b00051","article-title":"Phospholipidic Colchicinoids as Promising Prodrugs Incorporated into Enzyme-Responsive Liposomes: Chemical, Biophysical, and Enzymological Aspects","volume":"30","author":"Shchegravina","year":"2019","journal-title":"Bioconjug. Chem."}],"container-title":["Bioconjugate Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/pubs.acs.org\/doi\/pdf\/10.1021\/acs.bioconjchem.6c00278","content-type":"application\/pdf","content-version":"vor","intended-application":"unspecified"},{"URL":"https:\/\/pubs.acs.org\/bcches\/article-pdf\/37\/10\/1999\/68646136\/bc6c00278.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/pubs.acs.org\/bcches\/article-pdf\/37\/10\/1999\/68646136\/bc6c00278.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T08:11:48Z","timestamp":1792570308000},"score":1,"resource":{"primary":{"URL":"https:\/\/pubs.acs.org\/bcches\/article\/37\/10\/1999\/5438105\/Design-Synthesis-and-Biological-Evaluation-of-a"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,23]]},"references-count":43,"journal-issue":{"issue":"10","published-online":{"date-parts":[[2026,9,23]]},"published-print":{"date-parts":[[2026,10,21]]}},"URL":"https:\/\/doi.org\/10.1021\/acs.bioconjchem.6c00278","relation":{},"ISSN":["1043-1802","1520-4812"],"issn-type":[{"value":"1043-1802","type":"print"},{"value":"1520-4812","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,23]]}}}